Freestone Capital Holdings LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 5.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 114,054 shares of the biopharmaceutical company’s stock after purchasing an additional 6,206 shares during the quarter. Freestone Capital Holdings LLC’s holdings in Pfizer were worth $3,831,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Shine Investment Advisory Services Inc. acquired a new position in Pfizer in the 2nd quarter worth about $102,000. D. Scott Neal Inc. raised its holdings in Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares during the period. Herndon Capital Management LLC acquired a new position in Pfizer in the 2nd quarter worth about $120,000. Franklin Parlapiano Turner & Welch LLC acquired a new position in Pfizer in the 1st quarter worth about $121,000. Finally, Private Vista LLC raised its holdings in Pfizer by 2,277.3% in the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 190,933 shares during the period. 69.89% of the stock is owned by institutional investors.

In related news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the transaction, the insider now directly owns 145,649 shares in the company, valued at $5,097,715. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the transaction, the executive vice president now owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. Insiders sold 60,280 shares of company stock valued at $2,118,988 over the last 90 days. Company insiders own 0.06% of the company’s stock.

Several research firms have commented on PFE. UBS set a $40.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Wednesday. Deutsche Bank set a $38.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Wednesday. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Saturday, November 25th. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price objective for the company in a research note on Thursday, November 23rd. Finally, Jefferies Group set a $39.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $38.77.

Pfizer Inc. (NYSE:PFE) traded down $0.07 during mid-day trading on Thursday, hitting $35.56. The stock had a trading volume of 17,379,200 shares, compared to its average volume of 19,978,311. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $212,380.00, a price-to-earnings ratio of 14.25, a PEG ratio of 2.51 and a beta of 1.01. Pfizer Inc. has a 1-year low of $30.51 and a 1-year high of $36.78.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business’s revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.61 earnings per share. equities research analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were given a $0.32 dividend. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.60%. Pfizer’s dividend payout ratio (DPR) is presently 79.01%.

ILLEGAL ACTIVITY WARNING: “Freestone Capital Holdings LLC Has $3.83 Million Position in Pfizer Inc. (PFE)” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/12/07/freestone-capital-holdings-llc-has-3-83-million-position-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.